JP2012505905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505905A5 JP2012505905A5 JP2011532217A JP2011532217A JP2012505905A5 JP 2012505905 A5 JP2012505905 A5 JP 2012505905A5 JP 2011532217 A JP2011532217 A JP 2011532217A JP 2011532217 A JP2011532217 A JP 2011532217A JP 2012505905 A5 JP2012505905 A5 JP 2012505905A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkoxy
- alkyl
- pattern
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000002245 particle Substances 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims 2
- 230000036765 blood level Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- -1 cyano, hydroxy, acetyl Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 102000006991 Apolipoprotein B-100 Human genes 0.000 claims 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10648308P | 2008-10-17 | 2008-10-17 | |
| US61/106,483 | 2008-10-17 | ||
| PCT/US2009/060679 WO2010045361A1 (en) | 2008-10-17 | 2009-10-14 | Methods of reducing small, dense ldl particles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505905A JP2012505905A (ja) | 2012-03-08 |
| JP2012505905A5 true JP2012505905A5 (https=) | 2012-11-29 |
| JP5694941B2 JP5694941B2 (ja) | 2015-04-01 |
Family
ID=42106878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532217A Active JP5694941B2 (ja) | 2008-10-17 | 2009-10-14 | 小型高密度ｌｄｌ粒子を減少させる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20100152295A1 (https=) |
| EP (1) | EP2346498B1 (https=) |
| JP (1) | JP5694941B2 (https=) |
| KR (1) | KR20110091680A (https=) |
| CN (1) | CN102209532B (https=) |
| BR (1) | BRPI0920170A2 (https=) |
| CA (1) | CA2740874C (https=) |
| ES (1) | ES2712052T3 (https=) |
| MX (1) | MX2011004077A (https=) |
| TW (1) | TWI491392B (https=) |
| WO (1) | WO2010045361A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| EP2680859B1 (en) | 2011-03-02 | 2022-04-27 | Jerome Schentag | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| HK1224186A1 (zh) | 2013-11-20 | 2017-08-18 | Cymabay Therapeutics, Inc. | 纯阖家族型高胆固醇血症的治疗 |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| RS57970B1 (sr) | 2014-03-20 | 2019-01-31 | Cymabay Therapeutics Inc | Tretman intrahepatičkih holestatskih oboljenja |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| ES2859487T3 (es) * | 2016-10-05 | 2021-10-04 | Mitobridge Inc | Métodos para tratar las lesiones renales agudas |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE7897T1 (de) | 1979-09-05 | 1984-06-15 | Glaxo Group Limited | Phenol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| US7576131B2 (en) | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| EP1310494B1 (en) | 2000-08-11 | 2012-01-25 | Nippon Chemiphar Co., Ltd. | PPAR (delta) ACTIVATORS |
| AU2002224138A1 (en) | 2000-12-05 | 2002-06-18 | Nippon Chemiphar Co. Ltd. | Peroxisome proliferator activated receptor d activators |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| WO2002100351A2 (en) | 2001-06-11 | 2002-12-19 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a ppar-delta agonist |
| GB0121436D0 (en) * | 2001-09-04 | 2001-10-24 | Pfizer Ltd | Biomodulated multiparticulate formulations |
| US20060258683A1 (en) * | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| US20070037882A1 (en) | 2003-04-22 | 2007-02-15 | Astellas Pharma Inc. | Remedy for cerebral neurodegenerative diseases using ppar agonist |
| US7199259B2 (en) | 2003-06-20 | 2007-04-03 | Metabolex, Inc. | Resolution of α-(phenoxy)phenylacetic acid derivatives |
| WO2005042478A2 (en) * | 2003-09-19 | 2005-05-12 | Janssen Pharmaceutica, N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| WO2005115384A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
| US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
| MY147518A (en) * | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| RS57970B1 (sr) * | 2014-03-20 | 2019-01-31 | Cymabay Therapeutics Inc | Tretman intrahepatičkih holestatskih oboljenja |
| KR102374499B1 (ko) * | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
-
2009
- 2009-10-14 CA CA2740874A patent/CA2740874C/en active Active
- 2009-10-14 ES ES09821200T patent/ES2712052T3/es active Active
- 2009-10-14 WO PCT/US2009/060679 patent/WO2010045361A1/en not_active Ceased
- 2009-10-14 JP JP2011532217A patent/JP5694941B2/ja active Active
- 2009-10-14 CN CN200980144827.7A patent/CN102209532B/zh active Active
- 2009-10-14 KR KR1020117011217A patent/KR20110091680A/ko not_active Ceased
- 2009-10-14 BR BRPI0920170A patent/BRPI0920170A2/pt not_active Application Discontinuation
- 2009-10-14 EP EP09821200.4A patent/EP2346498B1/en active Active
- 2009-10-14 MX MX2011004077A patent/MX2011004077A/es active IP Right Grant
- 2009-10-15 US US12/579,996 patent/US20100152295A1/en not_active Abandoned
- 2009-10-16 TW TW098135183A patent/TWI491392B/zh active
-
2016
- 2016-01-13 US US14/995,024 patent/US20160324811A1/en not_active Abandoned
-
2018
- 2018-10-31 US US16/176,349 patent/US11007162B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505905A5 (https=) | ||
| JP2022512482A5 (https=) | ||
| JP2010077141A5 (https=) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2009504763A5 (https=) | ||
| EA201071034A1 (ru) | Новые макроциклические ингибиторы репликаций вируса гепатита с | |
| EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| JP2013508279A5 (https=) | ||
| JP2011057693A5 (https=) | ||
| JP2011507896A5 (https=) | ||
| JP2006524660A5 (https=) | ||
| WO2009063202A3 (en) | Use of crth2 antagonist compounds | |
| JP2009530398A5 (https=) | ||
| JP2018536710A5 (https=) | ||
| JP2009536191A5 (https=) | ||
| EP2090577A8 (en) | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | |
| JP2017530984A5 (https=) | ||
| JP2018505169A5 (https=) | ||
| JP2013540713A5 (https=) | ||
| JP2013512277A5 (https=) | ||
| JP2013508382A5 (https=) | ||
| JP2015501833A5 (https=) | ||
| JP2013519653A5 (https=) | ||
| AR084801A1 (es) | Formulaciones inmunosupresoras | |
| JP2013518036A5 (https=) |